Physician

Edward R. Arrowsmith, MD

According to 2025 Medicare claims, Edward Arrowsmith, MD (NPI: 1780632687) practices hematology/oncology in the Chattanooga, TN-GA market, with the plurality of this provider's patient population coming from Hamilton, TN. This provider's primary affiliated billing organization is TENNESSEE ONCOLOGY PLLC (NPI: 1811955917; TIN: 621647259) and primary practice location at 37403-2836. Arrowsmith is affiliated with the Main Street Rural Health Cedar ACO LLC (ACO ID: A5502), participating under the MSSP model.

Arrowsmith's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,521 traditional Medicare patients, billed 125,365 HCPCS/CPT codes, and received $3,000,717 in Medicare payments. The top billing code was 82728 (Ferritin (blood protein) level). Part D data shows 1,860 prescription claims across 302 beneficiaries totaling $6,322,933 in drug costs, led by Abiraterone Acetate (Abiraterone Acetate). DME data shows 45 claims. Open Payments data shows 84 records totaling $987,829. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,447,364 to $3,000,717. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,790,571 to $6,322,933. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $5,746 to $552.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	842	173,050	$1,447,364
2016	815	172,683	$1,392,732
2017	961	223,778	$2,159,678
2018	963	212,391	$2,258,576
2019	940	191,742	$2,663,402
2020	1,033	155,153	$1,932,059
2021	1,035	183,977	$3,605,003
2022	820	152,763	$2,230,412
2023	1,661	166,153	$2,549,301
2024	1,521	125,365	$3,000,717

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	209	1,093	$1,790,571
2016	175	1,089	$1,983,892
2017	215	1,425	$2,701,350
2018	260	1,697	$3,927,328
2019	263	1,390	$3,285,971
2020	236	1,312	$3,018,899
2021	271	1,482	$4,684,511
2022	268	1,409	$3,731,303
2023	291	1,743	$6,481,251
2024	302	1,860	$6,322,933

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	98	$2,941
2016	N/R	45	$1,810
2017	N/R	25	$4,320
2018	N/R	25	$3,476
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	40	$1,696
2023	N/R	17	$5,680
2024	N/R	45	$1,106

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
82728	Ferritin (blood protein) level	528	1,283	$13
80053	Blood test, comprehensive group of blood chemicals	1,040	3,763	$10
83550	Iron binding capacity	438	884	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	371	1,640	$8
83540	Iron level	440	886	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Abiraterone Acetate	Abiraterone Acetate	407	12,390	$907,522
Revlimid	Lenalidomide	34	952	$691,752
Imbruvica	Ibrutinib	40	1,120	$615,378
Jakafi	Ruxolitinib Phosphate	31	930	$476,207
Xtandi	Enzalutamide	34	1,020	$400,015

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	16	$673
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$188

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	39	$875	Bayer Healthcare Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	45	$986,954	Aveo Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Edward R. Arrowsmith, MD?

Tedicare shows public-source Medicare data for Edward R. Arrowsmith, MD (NPI 1780632687), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Edward R. Arrowsmith, MD have ACO affiliation data?

Edward R. Arrowsmith, MD is shown with ACO affiliation data for Main Street Rural Health Cedar ACO LLC (MSSP, ACO ID A5502).

What billing organization is linked to Edward R. Arrowsmith, MD?

Edward R. Arrowsmith, MD is linked to TENNESSEE ONCOLOGY PLLC (billing NPI 1811955917) in the available physician profile data.

Does Edward R. Arrowsmith, MD have Open Payments data?

Edward R. Arrowsmith, MD has 84 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.